ZA9810788B - Method and composition for the treatment and prevention of hyperuricemia - Google Patents

Method and composition for the treatment and prevention of hyperuricemia

Info

Publication number
ZA9810788B
ZA9810788B ZA9810788A ZA9810788A ZA9810788B ZA 9810788 B ZA9810788 B ZA 9810788B ZA 9810788 A ZA9810788 A ZA 9810788A ZA 9810788 A ZA9810788 A ZA 9810788A ZA 9810788 B ZA9810788 B ZA 9810788B
Authority
ZA
South Africa
Prior art keywords
hyperuricemia
prevention
treatment
composition
Prior art date
Application number
ZA9810788A
Inventor
Toshihiko Fujiwara
Koichi Iwasaki
Hiroyoshi Horikoshi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ZA9810788B publication Critical patent/ZA9810788B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA9810788A 1997-11-25 1998-11-25 Method and composition for the treatment and prevention of hyperuricemia ZA9810788B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32318297 1997-11-25

Publications (1)

Publication Number Publication Date
ZA9810788B true ZA9810788B (en) 1999-05-25

Family

ID=18151987

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810788A ZA9810788B (en) 1997-11-25 1998-11-25 Method and composition for the treatment and prevention of hyperuricemia

Country Status (23)

Country Link
US (1) US6353009B1 (en)
EP (1) EP0919232B1 (en)
KR (1) KR19990045531A (en)
AR (1) AR011231A1 (en)
AT (1) ATE278400T1 (en)
AU (1) AU744653B2 (en)
BR (1) BR9805012A (en)
CA (1) CA2254394C (en)
CZ (1) CZ378898A3 (en)
DE (2) DE69826811T4 (en)
ES (1) ES2230657T3 (en)
HK (1) HK1020259A1 (en)
HU (2) HUP9902721A2 (en)
ID (1) ID21332A (en)
IL (1) IL127219A (en)
NO (1) NO985484L (en)
NZ (1) NZ332895A (en)
PL (1) PL329893A1 (en)
RU (1) RU2190425C2 (en)
SA (1) SA99191266A (en)
TR (1) TR199802441A2 (en)
TW (1) TW592697B (en)
ZA (1) ZA9810788B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533534B2 (en) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Inhibitor of glycogen synthase kinase 3
AU3195700A (en) * 1999-05-27 2000-12-18 Tanabe Seiyaku Co., Ltd. Remedies for kidney diseases and method for screening the same
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6958355B2 (en) 2000-04-24 2005-10-25 Aryx Therapeutics, Inc. Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
AU2001294673A1 (en) * 2000-09-21 2002-04-02 Aryx Therapeutics Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis
CN101613321A (en) * 2002-03-05 2009-12-30 特兰斯泰克制药公司 The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction
WO2005000295A1 (en) * 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US20050025823A1 (en) * 2003-07-29 2005-02-03 Fong Andy A.T. Methods of use of herbal compositions
JP2005092923A (en) * 2003-09-12 2005-04-07 Renesas Technology Corp Semiconductor memory device
EP1778261A4 (en) 2004-07-21 2010-08-11 Univ Florida Compositions and methods for treatment and prevention of insulin resistance
CA2617161A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
MX2009010790A (en) * 2007-04-05 2009-10-29 Daiichi Sankyo Co Ltd Fused bicyclic heteroaryl derivatives.
RU2480463C1 (en) 2009-03-05 2013-04-27 Дайити Санкио Компани, Лимитед Pyridyloxy derivatives effective as peroxisome proliferator-activated receptor (ppar) gamma activator/modulator
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) * 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
RU2014134845A (en) * 2012-01-27 2016-03-20 Тейдзин Фарма Лимитед THERAPEUTIC AGAINST DIABETES
CA2912216A1 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
US20190152967A1 (en) * 2016-04-04 2019-05-23 The Schepens Eye Research Institute, Inc. Peroxisome proliferator-activated receptor gamma selective agonists for inhibition of retinal pigment epithelium degeneration or geographic atrophy

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS58118577A (en) 1982-01-07 1983-07-14 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (en) 1983-08-30 1985-03-22 Sankyo Co Ltd Thiazolidine derivative and its preparation
CN1003445B (en) 1984-10-03 1989-03-01 武田药品工业株式会社 The preparation method of thiazolidine diketone derivative
AR240698A1 (en) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
WO1986007056A1 (en) * 1985-05-21 1986-12-04 Pfizer Inc. Hypoglycemic thiazolidinediones
ZA873745B (en) 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
FI91869C (en) 1987-03-18 1994-08-25 Tanabe Seiyaku Co Process for the preparation of benzoxazole derivatives as antidiabetic agents
EP0295828A1 (en) 1987-06-13 1988-12-21 Beecham Group Plc Novel compounds
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US5194443A (en) 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
US5260445A (en) 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5120754A (en) 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
US4897405A (en) 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469383A (en) 1990-07-06 1992-03-04 Yamanouchi Pharmaceut Co Ltd Substituted thiazolidine derivative
GB9017218D0 (en) 1990-08-06 1990-09-19 Beecham Group Plc Novel compounds
WO1994001488A1 (en) * 1992-07-02 1994-01-20 Novo Nordisk A/S POLYMERIZATION OF LIGNIN AT ALKALINE pH
GB9223059D0 (en) 1992-11-04 1992-12-16 Bamford Excavators Ltd Intercooler apparatus
JP2845743B2 (en) 1992-12-28 1999-01-13 三菱化学株式会社 New naphthalene derivatives
JPH06211657A (en) 1993-01-21 1994-08-02 Mochida Pharmaceut Co Ltd Uric acid-excretory agent
HU228260B1 (en) 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
CA2157032C (en) * 1993-12-27 1999-09-28 Hisashi Shinkai Isoxazolidinedione derivative and use thereof
RU2151145C1 (en) * 1994-04-11 2000-06-20 Санкио Компани Лимитед Intermediate compound for synthesis of heterocyclic compounds showing antidiabetic activity
US5703096A (en) 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
IL118474A (en) 1995-06-01 2001-08-08 Sankyo Co Benzimidazole derivatives and pharmaceutical compositions containing the same
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus

Also Published As

Publication number Publication date
ES2230657T3 (en) 2005-05-01
HK1020259A1 (en) 2000-04-07
AR011231A1 (en) 2000-08-02
TR199802441A3 (en) 1999-10-21
HU9802721D0 (en) 1999-01-28
TW592697B (en) 2004-06-21
ID21332A (en) 1999-05-27
NZ332895A (en) 2001-04-27
TR199802441A2 (en) 1999-10-21
AU9410298A (en) 1999-06-17
DE69826811T2 (en) 2005-06-16
KR19990045531A (en) 1999-06-25
SA99191266A (en) 2005-12-03
CZ378898A3 (en) 1999-07-14
AU744653B2 (en) 2002-02-28
PL329893A1 (en) 1999-06-07
IL127219A (en) 2001-08-08
ATE278400T1 (en) 2004-10-15
DE69826811T4 (en) 2006-09-21
NO985484D0 (en) 1998-11-24
HUP9902721A2 (en) 1999-12-28
RU2190425C2 (en) 2002-10-10
EP0919232B1 (en) 2004-10-06
BR9805012A (en) 2000-03-21
HUP9802721A1 (en) 2000-03-28
DE69826811D1 (en) 2004-11-11
EP0919232A1 (en) 1999-06-02
CA2254394A1 (en) 1999-05-25
IL127219A0 (en) 1999-09-22
NO985484L (en) 1999-05-26
CA2254394C (en) 2009-11-17
US6353009B1 (en) 2002-03-05

Similar Documents

Publication Publication Date Title
HU9802721D0 (en) Method and composition for the treatment and prevention of hyperuricemia
IL127664A (en) Compositions for the treatment and prevention of cachexia
HK1048949A1 (en) Method and composition for the treatment of scars
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
EP0717592A4 (en) Method and composition for the treatment of apathy-amotivation syndrome
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
HK1031174A1 (en) Compositions and methods for treating diabetes
GB0015235D0 (en) Compositions for the treatment of skin and anorectal conditions
ZA988016B (en) Compounds methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
EP1239855A4 (en) Method for the prevention and/or treatment of atherosclerosis
IL141426A0 (en) Compositions and methods for the treatment of tumor
IL143212A0 (en) Compositions and methods for the treatment of tumor
HUP0102995A3 (en) Agents and method for the protective treatment of wood
AU2420101A (en) Method and composition for the treatment of pain
AU4107797A (en) Compounds for the treatment and prevention of diabetes
HUP0300043A3 (en) Method and composition for the treatment of pain
HUP9900436A3 (en) Installation and method for the treatment of wine-production efilvents
EP0963968A4 (en) Agent and method for surface treatment of calcium-base inorganic members
SI1097031T1 (en) Agents and method for the protective treatment of wood
AUPM421894A0 (en) Method and composition for the prevention and/or treatment of ulcers
HU9600327D0 (en) Pharmaceutical composition for treating or profilacting meteoropathy and different kinetoses
AUPO697197A0 (en) Composition and method of treatment
AUPO616097A0 (en) Composition and method of treatment
GB9608927D0 (en) Method of treatment and pharmaceutical composition